Hongbing Yang

发表

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects

J. Martinez-Picado, E. Giannoulatou, B. Angus, 2017, Journal of the International AIDS Society.

Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection.

B. Angus, J. Mak, R. Smyth, 2013, Journal of immunological methods.

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

C. Brander, N. Frahm, A. McMichael, 2015, PLoS pathogens.

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction

L. Dorrell, Hongbing Yang, Zoë R Wallace, 2018, Front. Immunol..

Discovery of a PCAF Bromodomain Chemical Probe

S. Knapp, O. Fedorov, P. Brennan, 2016, Angewandte Chemie.

Linking genotype to phenotype on beads: high throughput selection of peptides with biological function

G. Ogg, G. Stewart-Jones, L. Dorrell, 2013, Scientific Reports.

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors

B. Jakobsen, P. Molloy, L. Dorrell, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption

A. McMichael, P. Borrow, M. Davenport, 2009, AIDS.

Engineered affinity-enhanced immune-mobilising monoclonal T cell receptors (ImmTAVs) for HIV cure

B. Jakobsen, J. Frater, L. Dorrell, 2017 .

Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells

M. Nielsen, C. Brander, P. Borrow, 2015, European journal of immunology.

HLA-E–restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities

L. Picker, A. McMichael, P. Borrow, 2021, Science Immunology.

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)

B. Clotet, J. Martinez-Picado, C. Brander, 2019, EClinicalMedicine.

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.

A. McMichael, B. Angus, Hao Wu, 2012, The Journal of infectious diseases.

decline in HIV-1 infection

B. Angus, Hao Wu, T. Denny, 2012 .

Hypoxic microenvironment shapes HIV-1 replication and latency

P. Borrow, M. Ashcroft, J. McKeating, 2020, Communications Biology.

Transition From Long-Term Nonprogression to HIV-1 Disease Associated With Escape From Cellular Immune Control

Dorothy M. Lang, R. Kaul, S. Rowland-Jones, 2008, Journal of acquired immune deficiency syndromes.

Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy1

A. McMichael, P. Borrow, P. Bowness, 2007, The Journal of Immunology.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

A Randomized Comparison of Antiretroviral Therapy Alone Versus Antiretroviral Therapy with a 'Kick-and-Kill' Approach, on Measures of the HIV Reservoir Amongst Participants with Recent HIV Infection: The RIVER Trial

M. Johnson, M. Wills, A. Clarke, 2019, SSRN Electronic Journal.

Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine

Bette Korber, Tao Dong, Lucy Dorrell, 2007, PloS one.

Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine

S. Rowland-Jones, A. McMichael, P. Bowness, 2006, Journal of Virology.

Emergence of a distinct HIV‐specific IL‐10‐producing CD8+ T‐cell subset with immunomodulatory functions during chronic HIV‐1 infection

I. Williams, A. McMichael, P. Borrow, 2013, European journal of immunology.

Immune mobilising T cell receptors redirect polyclonal CD8+ T cells in chronic HIV infection to form immunological synapses

C. Eggeling, M. McCully, L. Dorrell, 2022, Scientific Reports.

HLA-E restricted, HIV-1 suppressing, Gag specific CD8+ T cells offer universal vaccine opportunities

L. Picker, A. McMichael, P. Borrow, 2020, bioRxiv.

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.

A. McMichael, T. Hanke, P. Hayes, 2010, Vaccine.

Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART

T. Scriba, H. McShane, C. Conlon, 2006, AIDS.

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen

S. Rowland-Jones, A. McMichael, P. Bowness, 2006, Retrovirology.

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

S. Rowland-Jones, A. McMichael, A. Iversen, 2005, AIDS.

Antiretroviral Therapy Driven by Vaccination during Highly Active T Cell Expansions + HIV-1-Specific CD8 Broad TCR Usage in Functional

A. McMichael, P. Borrow, P. Bowness, 2007 .

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4+ T cell responses

S. Rowland-Jones, A. McMichael, T. Hanke, 2006, European journal of immunology.

Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunode fi ciency Virus-1 Infection and Association With Gag-Speci fi c T-Cell Responses

S. Yerly, M. Johnson, L. Vandekerckhove, 2016 .

Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses

S. Yerly, M. Johnson, L. Vandekerckhove, 2015, Open forum infectious diseases.

Correction: Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine

B. Korber, A. McMichael, T. Hanke, 2011, PLoS ONE.

Short communication: broader T cell responses directed against human immunodeficiency virus type 1 in infected Chinese individuals through blood-borne transmission in comparison with mucosal transmission.

N. Goonetilleke, T. Dong, Xiaoning Xu, 2013, AIDS research and human retroviruses.

HLA-E–restricted SARS-CoV-2–specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation

P. Klenerman, A. McMichael, P. Borrow, 2023, Science Immunology.

Design and Pre-Clinical Evaluation of a Universal HIV-1

B. Korber, A. McMichael, T. Hanke, 2007 .

CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

A. McMichael, T. Rostron, C. Hatton, 2000, The Journal of clinical investigation.

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.

A. McMichael, B. Angus, Hao Wu, 2012, The Journal of infectious diseases.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions

T. Hanke, J. Frater, L. Dorrell, 2023, Scientific reports.

Development of a Universal T Cell Vaccine

B. Korber, A. McMichael, T. Hanke, 2008 .